Progyny (PGNY) Tops Q3 Earnings Estimates
Earnings Performance: Progyny (PGNY) reported quarterly earnings of $0.40 per share, exceeding estimates and showing significant growth from $0.16 a year ago, but its revenues of $286.63 million fell short of expectations.
Stock Outlook: Despite the positive earnings surprise, Progyny's stock has underperformed this year, with a Zacks Rank #4 (Sell) indicating expected further underperformance, influenced by unfavorable estimate revisions and the overall industry ranking.
Trade with 70% Backtested Accuracy
Analyst Views on PGNY
About PGNY
About the author
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
Is Progyny's 85.7% Increase in 2025 Already Reflected in Its Growth Narrative?
Progyny's Stock Performance: Progyny's share price has increased significantly, up 50.2% year-to-date and 85.7% over the past year, driven by a growing focus on fertility benefits and a favorable market for scalable healthcare platforms.
Valuation Insights: Despite the stock's strong performance, Progyny scores only 2 out of 6 on valuation checks, indicating that the market may have already priced in much of the positive news.
Discounted Cash Flow Analysis: A Discounted Cash Flow model suggests that Progyny is undervalued by approximately 62.5%, with an intrinsic value of about $71.04 per share compared to its current trading price.
Price to Earnings Ratio: Progyny's current PE ratio of 40.6x is significantly higher than industry averages, indicating that the stock may be overvalued relative to its fundamentals, as the fair PE ratio is estimated at 26.3x.
Noteworthy PGNY Put and Call Options Set for August 2026
Put Contract Overview: The $25.00 put contract for PGNY has a bid of $2.80, allowing investors to buy shares at a cost basis of $22.20, which is attractive compared to the current price of $26.19. There is a 65% chance the contract may expire worthless, potentially yielding an 11.20% return on cash commitment.
Call Contract Overview: The $30.00 call contract has a bid of $2.70, offering a potential total return of 24.86% if the stock is called away by August 2026. The contract is out-of-the-money by approximately 15%, with a 52% chance of expiring worthless, which would still provide a 10.31% additional return.
Volatility Insights: The implied volatility for the put contract is 51% and for the call contract is 50%, while the actual trailing twelve-month volatility is calculated at 47%, indicating a stable trading environment for PGNY.
YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a potential 16.69% annualized return and the call offering a 15.36% annualized return if the contracts expire worthless.
Progyny (PGNY) Receives Upgrade to Buy: Key Information You Need to Know
Zacks Rank Upgrade: Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which are crucial for stock price movements.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Progyny has increased by 8% over the past three months, reflecting analysts' growing confidence in the company's earnings potential.
Investment Strategy: The Zacks rating system, known for its strong track record, categorizes stocks based on earnings estimate revisions, with only the top 20% receiving a "Buy" or "Strong Buy" rating, suggesting Progyny's potential for market-beating returns.
Market Opportunities: The article highlights the potential for significant returns from lesser-known stocks, with previous recommendations achieving impressive gains, encouraging investors to consider these opportunities.
Options Trading for Progyny (PGNY) in the First Week of January 2026
Put Contract Overview: The $20.00 put contract for PGNY has a bid of 15 cents, allowing investors to buy shares at a cost basis of $19.85, which is a 19% discount from the current price of $24.84. There is an 86% chance the contract may expire worthless, offering a potential 0.75% return on cash commitment.
Call Contract Overview: The $30.00 call contract has a bid of 20 cents, and if shares are purchased at $24.84 and the call is sold, it could yield a total return of 21.58% if exercised by January 2026. There is a 79% chance this contract may also expire worthless, providing a 0.81% additional return.
Volatility Insights: The implied volatility for the put contract is 68%, while the call contract has an implied volatility of 56%. The actual trailing twelve-month volatility is calculated at 48%.
YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 6.22% annualized return and the call offering a 6.68% annualized return if they expire worthless.
Is Progyny (PGNY) a Strong Growth Investment? Here Are 3 Reasons to Agree.
Growth Stocks Overview: Growth stocks are appealing due to their potential for above-average financial growth, but they come with higher risks and volatility, making it challenging to identify the right ones.
Progyny's Performance: Progyny (PGNY) is highlighted as a strong growth stock, boasting a projected EPS growth of 500% this year and an asset utilization ratio of 1.75, significantly outperforming the industry average.
Earnings Estimate Revisions: The upward trend in earnings estimate revisions for Progyny has contributed to its Zacks Rank of #2 (Buy) and a Growth Score of A, indicating strong potential for stock price appreciation.
Investment Recommendations: Zacks Investment Research suggests that Progyny is well-positioned for outperformance, and they recommend considering it alongside other top stock picks for significant returns in the near future.
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
Is Progyny's 85.7% Increase in 2025 Already Reflected in Its Growth Narrative?
Progyny's Stock Performance: Progyny's share price has increased significantly, up 50.2% year-to-date and 85.7% over the past year, driven by a growing focus on fertility benefits and a favorable market for scalable healthcare platforms.
Valuation Insights: Despite the stock's strong performance, Progyny scores only 2 out of 6 on valuation checks, indicating that the market may have already priced in much of the positive news.
Discounted Cash Flow Analysis: A Discounted Cash Flow model suggests that Progyny is undervalued by approximately 62.5%, with an intrinsic value of about $71.04 per share compared to its current trading price.
Price to Earnings Ratio: Progyny's current PE ratio of 40.6x is significantly higher than industry averages, indicating that the stock may be overvalued relative to its fundamentals, as the fair PE ratio is estimated at 26.3x.
Noteworthy PGNY Put and Call Options Set for August 2026
Put Contract Overview: The $25.00 put contract for PGNY has a bid of $2.80, allowing investors to buy shares at a cost basis of $22.20, which is attractive compared to the current price of $26.19. There is a 65% chance the contract may expire worthless, potentially yielding an 11.20% return on cash commitment.
Call Contract Overview: The $30.00 call contract has a bid of $2.70, offering a potential total return of 24.86% if the stock is called away by August 2026. The contract is out-of-the-money by approximately 15%, with a 52% chance of expiring worthless, which would still provide a 10.31% additional return.
Volatility Insights: The implied volatility for the put contract is 51% and for the call contract is 50%, while the actual trailing twelve-month volatility is calculated at 47%, indicating a stable trading environment for PGNY.
YieldBoost Concept: Both the put and call contracts offer a "YieldBoost," with the put providing a potential 16.69% annualized return and the call offering a 15.36% annualized return if the contracts expire worthless.
Progyny (PGNY) Receives Upgrade to Buy: Key Information You Need to Know
Zacks Rank Upgrade: Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook on its earnings estimates, which are crucial for stock price movements.
Earnings Estimate Revisions: The Zacks Consensus Estimate for Progyny has increased by 8% over the past three months, reflecting analysts' growing confidence in the company's earnings potential.
Investment Strategy: The Zacks rating system, known for its strong track record, categorizes stocks based on earnings estimate revisions, with only the top 20% receiving a "Buy" or "Strong Buy" rating, suggesting Progyny's potential for market-beating returns.
Market Opportunities: The article highlights the potential for significant returns from lesser-known stocks, with previous recommendations achieving impressive gains, encouraging investors to consider these opportunities.
Options Trading for Progyny (PGNY) in the First Week of January 2026
Put Contract Overview: The $20.00 put contract for PGNY has a bid of 15 cents, allowing investors to buy shares at a cost basis of $19.85, which is a 19% discount from the current price of $24.84. There is an 86% chance the contract may expire worthless, offering a potential 0.75% return on cash commitment.
Call Contract Overview: The $30.00 call contract has a bid of 20 cents, and if shares are purchased at $24.84 and the call is sold, it could yield a total return of 21.58% if exercised by January 2026. There is a 79% chance this contract may also expire worthless, providing a 0.81% additional return.
Volatility Insights: The implied volatility for the put contract is 68%, while the call contract has an implied volatility of 56%. The actual trailing twelve-month volatility is calculated at 48%.
YieldBoost Concept: Both the put and call contracts offer potential YieldBoosts, with the put providing a 6.22% annualized return and the call offering a 6.68% annualized return if they expire worthless.
Is Progyny (PGNY) a Strong Growth Investment? Here Are 3 Reasons to Agree.
Growth Stocks Overview: Growth stocks are appealing due to their potential for above-average financial growth, but they come with higher risks and volatility, making it challenging to identify the right ones.
Progyny's Performance: Progyny (PGNY) is highlighted as a strong growth stock, boasting a projected EPS growth of 500% this year and an asset utilization ratio of 1.75, significantly outperforming the industry average.
Earnings Estimate Revisions: The upward trend in earnings estimate revisions for Progyny has contributed to its Zacks Rank of #2 (Buy) and a Growth Score of A, indicating strong potential for stock price appreciation.
Investment Recommendations: Zacks Investment Research suggests that Progyny is well-positioned for outperformance, and they recommend considering it alongside other top stock picks for significant returns in the near future.
